Gross-Goupil M - Search Results

1

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.

2

Incidence of brain metastases in renal cell carcinoma treated with sorafenib.

Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Massard C, et al. Ann Oncol. 2010 May;21(5):1027-31. doi: 10.1093/annonc/mdp411. Epub 2009 Oct 22. Ann Oncol. 2010. PMID: 19850637 Free article. Clinical Trial.

3

Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.

Roubaud G, Gross-Goupil M, Wallerand H, de Clermont H, Dilhuydy MS, Ravaud A. Roubaud G, et al. Oncology. 2011;80(3-4):214-8. doi: 10.1159/000329078. Epub 2011 Jul 1. Oncology. 2011. PMID: 21720184

4

Targeted therapies in metastatic renal cell carcinoma: overview of the past year.

Gross-Goupil M, Massard C, Ravaud A. Gross-Goupil M, et al. Curr Urol Rep. 2012 Feb;13(1):16-23. doi: 10.1007/s11934-011-0232-y. Curr Urol Rep. 2012. PMID: 22139625 Review.

5

Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma.

Ravaud A, Gross-Goupil M. Ravaud A, et al. Cancer Treat Rev. 2012 Dec;38(8):996-1003. doi: 10.1016/j.ctrv.2012.01.003. Epub 2012 Feb 12. Cancer Treat Rev. 2012. PMID: 22330762 Review.

6

Lapatinib and renal cell carcinoma.

Gross-Goupil M, Bernhard JC, Ravaud A. Gross-Goupil M, et al. Expert Opin Investig Drugs. 2012 Nov;21(11):1727-32. doi: 10.1517/13543784.2012.713935. Epub 2012 Aug 9. Expert Opin Investig Drugs. 2012. PMID: 22876762 Review.

7

Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.

Daste A, Gross-Goupil M, Roca S, Bernhard JC, Ravaud A. Daste A, et al. Target Oncol. 2014 Mar;9(1):81-4. doi: 10.1007/s11523-012-0245-6. Epub 2013 Jan 3. Target Oncol. 2014. PMID: 23283668 Review.

8

Optimal management of renal cell carcinoma in the elderly: a review.

Quivy A, Daste A, Harbaoui A, Duc S, Bernhard JC, Gross-Goupil M, Ravaud A. Quivy A, et al. Clin Interv Aging. 2013;8:433-42. doi: 10.2147/CIA.S30765. Epub 2013 Apr 19. Clin Interv Aging. 2013. PMID: 23626463 Free PMC article. Review.

9

Emerging antiangiogenics for renal cancer.

Domblides C, Gross-Goupil M, Quivy A, Ravaud A. Domblides C, et al. Expert Opin Emerg Drugs. 2013 Dec;18(4):495-511. doi: 10.1517/14728214.2013.858697. Expert Opin Emerg Drugs. 2013. PMID: 24274612 Review.

10

Protein kinase inhibitors in renal cell carcinoma.

Daste A, Grellety T, Gross-Goupil M, Ravaud A. Daste A, et al. Expert Opin Pharmacother. 2014 Feb;15(3):337-51. doi: 10.1517/14656566.2014.869210. Epub 2013 Dec 16. Expert Opin Pharmacother. 2014. PMID: 24328606 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

175 results

Search Page